Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by American Society of Clinical Oncology
Bristol-Myers Squibb
Eli Lilly and Company
Genentech, Inc.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
American Society of Clinical Oncology Identifier:
First received: February 11, 2016
Last updated: April 7, 2017
Last verified: April 2017
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

Condition Intervention Phase
Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors
Drug: Erlotinib
Drug: Axitinib
Drug: Bosutinib
Drug: Crizotinib
Drug: Palbociclib
Drug: Sunitinib
Drug: Temsirolimus
Drug: Trastuzumab and Pertuzumab
Drug: Vemurafenib and Cobimetinib
Drug: Vismodegib
Drug: Cetuximab
Drug: Dasatinib
Drug: Regorafenib
Drug: Olaparib
Drug: Pembrolizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Resource links provided by NLM:

Further study details as provided by American Society of Clinical Oncology:

Primary Outcome Measures:
  • Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria [ Time Frame: Assessed at 16 weeks of treatment ]
    Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.

Secondary Outcome Measures:
  • Overall survival (OS) [ Time Frame: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years ]
    OS will be estimated using the Kaplan-Meier method

Estimated Enrollment: 1030
Study Start Date: March 2016
Estimated Primary Completion Date: March 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Group 1 (VEGFR)
Participants receive axitinib - dosage, frequency and duration per label VEGFR mutation, amplification or overexpression)
Drug: Axitinib
Other Name: Inlyta
Group 2 (Bcr-abl, SRC, LYN, LCK)
Participants receive bosutinib- dosage, frequency and duration per label Bcr-abl, SRC, LYN, LCK mutations
Drug: Bosutinib
Other Name: Bosulif
Group 3 (ALK, ROS1, MET)
Participants receive crizotinib - dosage, frequency and duration per label ALK, ROS1, MET mutations
Drug: Crizotinib
Other Name: Xalkori
Group 4 (CDKN2A/p16, CDK4, CDK6)
Participants receive palbociclib - dosage, frequency and duration per label CDKN2A/p16 loss, CDK4, CDK6 amplifications
Drug: Palbociclib
Other Name: Ibrance
Participants receive sunitinib - dosage, frequency and duration per label CSF1R, PDGFR, VEGFR mutations
Drug: Sunitinib
Other Name: Sutent
Group 6 (mTOR, TSC)
Participants receive temsirolimus - dosage, frequency and duration per label mTOR, TSC mutations
Drug: Temsirolimus
Other Name: Torisel
Group 7 (EGFR)
Participants receive erlotinib - dosage, frequency and duration per label EGFR mutations
Drug: Erlotinib
Other Name: Tarceva
Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label (ERBB2 amplifications)
Drug: Trastuzumab and Pertuzumab
Other Name: Herceptin and Perjeta
Group 9 (BRAFV600E)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label BRAFV600E mutations
Drug: Vemurafenib and Cobimetinib
Other Name: Zelboraf and Cotellic
Group 10 (PTCH1)
Participants receive vismodegib - dosage, frequency and duration per label PTCH1 deletion or inactivating mutations
Drug: Vismodegib
Other Name: Erivedge
Group 11 (KRAS, NRAS and BRAF)
Participants receive cetuximab - dosage, frequency and duration per label KRAS, NRAS and BRAF wildtype
Drug: Cetuximab
Other Name: Erbitux
Group 12 (Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1)
Participants receive dasatinib- dosage, frequency and duration per label Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1 mutations
Drug: Dasatinib
Other Name: Sprycel
Participants receive regorafenib- dosage, frequency and duration per label RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFRβ, RAF-1, BRAF mutations/amplifications
Drug: Regorafenib
Other Name: Stivarga
Group 14 (BRCA1/BRCA2; ATM)
Participants receive olaparib- dosage, frequency and duration per label Germline or somatic BRCA1/BRCA2 inactivating mutations; ATM mutations or deletions
Drug: Olaparib
Other Name: Lynparza
Group 15 (POLE/POLD1;high mutational load)
Participants receive pembrolizumab- dosage, frequency and duration per label Note: high mutational load defined per protocol
Drug: Pembrolizumab
Other Name: Keytruda

Detailed Description:
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
  • Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG )criteria)
  • Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:

    1. Absolute neutrophil count ≥ 1.5 x 106/µl
    2. Hemoglobin > 9.0 g/dl
    3. Platelets > 75,000/µl
    4. Total bilirubin < 2.0 mg/ dl
    5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
  • Patients must have measurable or evaluable disease (per RECIST v1.1 for solid tumor, Lugano criteria for non Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined, per RECIST 1.1, as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral computed tomography (CT) scan, Magnetic Resonance Imaging (MRI), or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patients who have assessable disease by physical or radiographic examination but do not meet these definitions of measurable disease are eligible and will be considered to have evaluable disease. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only) are NOT eligible
  • Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified, College of American Pathologists (CAP) -accredited, New York State accredited (for labs offering services to residents of NY) laboratory that has registered the test with the National Institutes of Health (NIH) Genetic Test Registry or has established an integration with the TAPUR platform. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
  • Ability to understand and the willingness to sign a written informed consent document
  • Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol
  • For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome
  • Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse

Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1

Exclusion Criteria:

  • Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
  • Patients with primary brain tumors are excluded. Patients with known progressive brain metastases determined by serial imaging or declining neurologic function in the opinion of the treating physician are not eligible. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.

Note: there are additional exclusion criteria that may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02693535

Contact: Pam Mangat, MS

United States, Arizona
Cancer Treatment Centers of America-Phoenix Recruiting
Phoenix, Arizona, United States, 85338
Contact: Jessica Coats    623-207-3899   
Principal Investigator: Glen Weiss, MD         
United States, Georgia
Cancer Treatment Centers of America - Atlanta Recruiting
Atlanta, Georgia, United States, 30265
Contact: Lai Reed    770-400-6077   
Principal Investigator: Ricardo Alvarez, MD         
United States, Illinois
Cancer Treatment Centers of America-Chicago Recruiting
Chicago, Illinois, United States, 60099
Contact: Malini Shankar    847-731-4143   
Principal Investigator: Eugene Ahn, MD         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Cancer AnswerLine Nurses    800-865-1125   
Cancer Research Consortium of West Michigan Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Connie Szczepanek, RN    616-391-1230   
Principal Investigator: Kathleen J. Yost, MD         
Michigan Cancer Research Consortium Recruiting
Traverse City, Michigan, United States, 48341
Contact: Beth LaVasseur, RN, MS    734-712-5658   
Contact    877-590-5995      
Principal Investigator: Philip Stella, MD         
United States, Nebraska
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Sarah Kirke    402-559-8065   
Principal Investigator: Alissa Marr, MD         
United States, North Carolina
Carolina's HealthCare System's Levine Cancer Institute Recruiting
Charlotte, North Carolina, United States, 28277
Contact: Kelly Bumgarner, RN, CCRP    704-403-2520   
Principal Investigator: Edward S. Kim, MD         
United States, North Dakota
Sanford Health- Bismarck Recruiting
Bismarck, North Dakota, United States, 58501
Contact: John Reynolds, MD    701-323-5741   
Principal Investigator: John Reynolds, MD         
Sanford Health- Fargo Recruiting
Fargo, North Dakota, United States, 58122
Contact: Anu Gaba, MD    701-234-6161   
Principal Investigator: Anu Gaba, MD         
United States, Oklahoma
Cancer Treatment Centers of America-Tulsa Recruiting
Tulsa, Oklahoma, United States, 74133
Contact: Faye Biggs    918-286-5448   
Principal Investigator: Theodore Pollock, DO         
United States, Oregon
Providence Health & Services Not yet recruiting
Portland, Oregon, United States, 97213
Contact: Katie Tripp    503-215-2614   
Principal Investigator: Walter Urba, MD         
United States, Pennsylvania
Cancer Treatment Centers of America-Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19124
Contact: Marianne Bonner    215-537-4881   
Principal Investigator: Pamela Crilley, DO         
United States, South Dakota
Sanford Cancer Center Oncology Clinic and Pharmacy Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Steven Powell, MD    605-328-5000   
Principal Investigator: Steven Powell, MD         
United States, Utah
Intermountain Healthcare Recruiting
Salt Lake City, Utah, United States, 84107
Contact: Jennifer Demko    801-507-3633   
Contact: Lori Grimm-Bundy    435.688.4168   
Principal Investigator: Craig Nichols, M.D.         
Principal Investigator: Derrick Haslem, M.D.         
United States, Washington
Swedish Cancer Institute Recruiting
Seattle, Washington, United States, 98104
Contact: Lauren Summers    206-386-2301   
Principal Investigator: Thomas Brown, MD, MBA         
Sponsors and Collaborators
American Society of Clinical Oncology
Bristol-Myers Squibb
Eli Lilly and Company
Genentech, Inc.
Merck Sharp & Dohme Corp.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: American Society of Clinical Oncology Identifier: NCT02693535     History of Changes
Other Study ID Numbers: Pro00014171
Study First Received: February 11, 2016
Last Updated: April 7, 2017

Keywords provided by American Society of Clinical Oncology:
precision medicine
targeted therapy

Additional relevant MeSH terms:
Multiple Myeloma
Lymphoma, Non-Hodgkin
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lymphatic Diseases
Erlotinib Hydrochloride
Crizotinib processed this record on April 21, 2017